R25
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 12
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.450
- MYC_TARGETS_V1+0.410
- MYC_TARGETS_V2+0.410
- G2M_CHECKPOINT+0.310
- OXIDATIVE_PHOSPHORYLATION+0.250
- DNA_REPAIR+0.230
- CHOLESTEROL_HOMEOSTASIS+0.180
- ESTROGEN_RESPONSE_LATE+0.170
- ADIPOGENESIS+0.150
- ANDROGEN_RESPONSE+0.150
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.550
- ALLOGRAFT_REJECTION-0.430
- INTERFERON_GAMMA_RESPONSE-0.430
- IL6_JAK_STAT3_SIGNALING-0.340
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.320
- COMPLEMENT-0.300
- INFLAMMATORY_RESPONSE-0.280
- PROTEIN_SECRETION-0.250
- UV_RESPONSE_DN-0.240
- KRAS_SIGNALING_UP-0.210
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-L3-A524-01A-11R-A262-07 | — | cohortSQ2 | 0.880 |
| 2 | TCGA-85-8354-01A-31R-2326-07 | — | cohortSQ2 | 0.879 |
| 3 | TCGA-77-6845-01A-11R-1949-07 | — | cohortSQ2 | 0.874 |
| 4 | e235012b-4b29-478a-abad-6a70cd949cfa | — | — | 0.872 |
| 5 | C3N-02434 | — | cohortSQ2 | 0.868 |
| 6 | TCGA-79-5596-01A-31R-1949-07 | — | cohortSQ2 | 0.864 |
| 7 | MNG517 | — | — | 0.861 |
| 8 | ae8e545c-f6ab-40e2-8122-162eab4b2724 | — | — | 0.859 |
| 9 | TCGA-77-8153-01A-11R-2403-07 | — | cohortSQ2 | 0.857 |
| 10 | C3N-04155 | — | cohortSQ2 | 0.854 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 25 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.450 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.410 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.410 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.310 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.250 | Remibrutinib | — uncovered |
| DNA_REPAIR | 0.230 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.180 | Remibrutinib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.170 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.150 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.150 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.150 | Inavolisib | — uncovered |
| HYPOXIA | 0.140 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.130 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.130 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.120 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.120 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.110 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.080 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.070 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.060 | Remibrutinib | — uncovered |